3 results about "Transformation cell" patented technology

The invention relates to the technical field of molecular biology, and provides an eukaryotic expression vector for expressing a fully human anti-RhD antibody, a cell strain and application of the eukaryotic expression vector. The eukaryotic expression vector disclosed by the invention is a recombinant plasmid and can express an anti-RhD antibody; genes of a heavy chain and a light chain of the anti-RhD antibody are located on the eukaryotic expression vector; the nucleotide sequence of the recombinant plasmid is as shown in SEQ ID NO. 1. The invention also comprises a cell strain obtained by transfecting the eukaryotic expression vector into a host cell and the expressed anti-D IgG protein. According to the invention, the light chain and the heavy chain of the anti-human red blood cell RhD antibody are constructed on the same plasmid, so that the phenomenon of improper matching of the light chain and the heavy chain of the antibody protein in the transfection process can be avoided, and the anti-D IgG protein with high expression efficiency and better functionality is obtained. Through stable transfection screening, a stably transformed cell strain with relatively strong immunogenicity is obtained and can be used for large-scale production.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The invention discloses a method for reprogramming melanocytes into fibroblast-like cells and application, and the method comprises the following steps: inoculating melanocytes into a pore plate, and generating melanin under the induction of a conditioned medium; s2, respectively adding an astragalus extract, astragaloside, astragalus polysaccharide and astragalus flavone into the pore plate in S1, and observing the cell morphology after 48 hours; optimizing and screening conditions for growing into fibroblast-like cells, and performing high-throughput sequencing and screening on astragalus membranaceus small molecular compounds for transforming cells; the optimized astragalus membranaceus small molecule compound is used for directly reprogramming melanocytes into fibroblast-like cells, and the expression of the melanocytes and fibroblast related markers is identified through immunofluorescence. According to the method disclosed by the invention, a workshop for producing melanin is changed into a factory for producing collagen, and the safety problem caused by introducing exogenous gene editing is not involved.